William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer (mHSPC).
Interim results from the ENZAMET trial, which were presented in a plenary session at the 2019 ASCO Annual Meeting, demonstrated a 3-year overall survival rate of 80% in patients treated with androgen deprivation therapy plus enzalutamide (Xtandi) compared with 72% in those treated with first-generation nonsteroidal antiandrogens.
These results were not surprising as abiraterone acetate (Zytiga), an agent similar to enzalutamide, showed a comparable survival benefit in the phase III STAMPEDE and LATITUDE trials, says Oh.
Notably, patients in the ENZAMET trial were allowed to receive concurrent chemotherapy. However, the survival benefit with enzalutamide appeared to be restricted to patients who did not receive concurrent chemotherapy, suggesting that there may be negative cross reactivity between chemotherapy and enzalutamide, says Oh.
As such, dual therapy with androgen receptor—targeted agents and chemotherapy is not a standard of care, concludes Oh.